The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas.
10.3340/jkns.2016.0102.001
- Author:
Brian SNELLING
1
;
Ashish H SHAH
;
Simon BUTTRICK
;
Ronald BENVENISTE
Author Information
1. Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. RBenveniste@med.miami.edu
- Publication Type:Original Article
- Keywords:
Glioma;
Tumor progression;
Radiation necrosis;
Magnetic resonance perfusion
- MeSH:
Consensus;
Disease Progression;
Follow-Up Studies;
Glioma*;
Humans;
Perfusion Imaging*;
Perfusion*;
Retrospective Studies;
Sensitivity and Specificity
- From:Journal of Korean Neurosurgical Society
2017;60(1):15-20
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Diagnosing tumor progression and pseudoprogression remains challenging for many clinicians. Accurate recognition of these findings remains paramount given necessity of prompt treatment. However, no consensus has been reached on the optimal technique to discriminate tumor progression. We sought to investigate the role of magnetic resonance perfusion (MRP) to evaluate tumor progression in glioma patients. METHODS: An institutional retrospective review of glioma patients undergoing MRP with concurrent clinical follow up visit was performed. MRP was evaluated in its ability to predict tumor progression, defined clinically or radiographically, at concurrent clinical visit and at follow up visit. The data was then analyzed based on glioma grade and subtype. RESULTS: A total of 337 scans and associated clinical visits were reviewed from 64 patients. Sensitivity, specificity, positive and negative predictive value were reported for each tumor subtype and grade. The sensitivity and specificity for high-grade glioma were 60.8% and 87.8% respectively, compared to low-grade glioma which were 85.7% and 89.0% respectively. The value of MRP to assess future tumor progression within 90 days was 46.9% (sensitivity) and 85.0% (specificity). CONCLUSION: Based on our retrospective review, we concluded that adjunct imaging modalities such as MRP are necessary to help diagnose clinical disease progression. However, there is no clear role for stand-alone surveillance MRP imaging in glioma patients especially to predict future tumor progression. It is best used as an adjunctive measure in patients in whom progression is suspected either clinically or radiographically.
